Biomea FusionBMEA +7.32%31 Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 146 Biotechnology companies, Biomea Fusion ranks worse than 684930.82% on this metric.
As of today (2026-06-27), the Forward Annual Dividend Yield of Biomea Fusion is 0.00%.
As of today (2026-06-27), the Trailing Annual Dividend Yield of Biomea Fusion is 0.00%.
BMEA's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Biomea Fusion Forward Dividend Yield % Related Terms
BMEA vs VRCA, PMN, SEER: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Biomea Fusion's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomea Fusion Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomea Fusion's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Biomea Fusion's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Biomea Fusion (BMEA) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biomea Fusion and its competitors. According to the industry distribution chart, Biomea Fusion ranks #999999 out of 146 companies in the Biotechnology industry.
Is Biomea Fusion's Forward Dividend Yield % too high?
Biomea Fusion's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Biomea Fusion ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Forward Dividend Yield % compare to VRCA and PMN?
According to the Biotechnology industry distribution chart, Biomea Fusion ranks #999999 out of 146 companies for Forward Dividend Yield %. This places Biomea Fusion in the lower half of its industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Biomea Fusion and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomea Fusion's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score
Get the complete analysis for BMEA
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMEA has been successfully added to your 